BELLUS Health Inc. announced today the results of the phase I clinical study for NRM8499, a prodrug of tramiprosate, intended for the treatment of Alzheimer's disease (the "Phase I Study"). The Phase I Study investigated the safety, tolerability and pharmacokinetic profile of NRM8499 as compared to tramiprosate in a group of 67 young and elderly healthy subjects. Results of the Phase I Study indicated that NRM8499 was safe and well tolerated at the intended therapeutic dose. Moreover, the gastrointestinal tolerability and pharmacokinetic profile of tramiprosate, with regards to the inter-individual variability in drug systemic exposure, were meaningfully improved with NRM8499 when compared to the administration of an equivalent dose of tramiprosate.
"We are pleased with the results of the NRM8499 phase I clinical study," said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. "The results show a solid potential for pursuing NRM8499 for the treatment of Alzheimer's disease."
The role of geroscience in understanding Alzheimer’s Disease